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Abstract 
Each year there are approximately 1.3 million new or recurrent cases of myocardial 
infarction or heart attack and over 400,000 of these cases result in death. Many who survive must 
undergo invasive heart surgery to repair the damaged tissue. The goal of this project will be to 
design an efficient and safe system to get the cell seeded microthreads to the patient. Cell therapy is 
a technology that is pivotal to many new medical procedures that are incredibly beneficial. More 
specifically, human mesenchymal stem cells (hMSCs) have the potential to be turned into living 
tissue that can replace dead or damaged cells. These engineered cells are advantageous because they 
do not run the risk of being rejected by the patient. The research being done at WPI uses fibrin 
microthreads as a delivery vehicle for hMSCs. The current delivery device and bioreactor for these 
microthreads, a small piece of medical tubing with plastic clamps, is rudimentary in design. There is 
currently no optimal way to prepare, ship, and store cells to be used in these types of procedures. 
Sterility, viability and safety are among a few of the major problems that must be addressed. The 
development of a device and system that could account for these issues would allow for the 
progression of many cell therapies and other techniques that are currently being studied. 
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1.0 Introduction 
Cell therapy is a technology that is pivotal to many new medical procedures that are 
incredibly beneficial. Many researchers have had great results using cell therapies to heal patients 
who are suffering in a number of ways. More specifically, human mesenchymal stem cells (hMSCs) 
have the potential to be turned into living tissue that can replace dead or damaged cells. These 
engineered cells are advantageous because they do not run the risk of being rejected by the patient. 
Research is currently being conducted, at Worcester Polytechnic Institute, on hMSCs to repair dead 
heart tissue that results from a heart attack. About 295,000 people year in the US suffer a myocardial 
infarction (out of hospital cardiac arrest) and a high percent must undergo invasive heart surgery to 
repair the damaged tissue. After a heart attack, part of the heart tissue dies. This dead tissue in the 
heart is very different from healthy living tissue. Dead heart tissue can be stiff and does not expand 
or contract very easily.  
The research being done at WPI uses fibrin microthreads as a delivery mechanism for 
hMSCs. The current delivery device and bioreactor for these microthreads, contains a small piece of 
salastic (medical) tubing with plastic clamps, it is considered rudimentary in design and can only hold 
one microthread at a time. With continued success, this therapeutic cardiovascular procedure will 
soon be moving to clinical trials. There is currently no optimal way to prepare, ship, and store these 
cells that are used in these types of procedures. Sterility, viability and safety are among a few of the 
major problems that need to be addressed. Another aspect is the ease of use for the doctors who 
will be using and delivering the cells; In addition transporting the cells from the lab to the clinic, and 
their storage on site, must also be taken into consideration. The system currently being used was 
designed simply with lab technicians in mind and does not take into account these crucial factors 
mentioned previously. 
To allow for further progression of cell therapy techniques a device must be developed that 
takes in the previously mentioned issues. The goal of this project will be to design an efficient and 
safe system to get the cell seeded microthreads to the patient, and an ideal method of storage and 
administration of the cell seeded microthreads will be developed. 
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2.0 Background 
 In this chapter background knowledge that pertains to the project and initial client statement 
will be explored. Research and knowledge about the heart and myocardial infarction as well as 
hMSCs, microthreads and tissue engineering were gathered and completed into this chapter. 
2.1. The Heart 
The heart is a myogenic muscular organ that is found in all animals with a circulatory system 
(Anatomy of the Human Heart, 2010). It is responsible for operating in conjunction with the 
circulatory system to pump blood and oxygen throughout the entire body. The heart is located in the 
chest cavity just behind the breastbone and in between the lungs, and it is divided into four main 
chambers (the left and right atrial and the left and right ventricles; see Figure 1: Heart ). The atrial 
receives the blood and the ventricles pump the blood from the heart to different organs in the body 
(The Human Heart, 2010). The heart is a vital organ that can be damaged by a variety of factors 
which lead to serious health problems such as myocardial infarction (Heart, 2010) 
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Figure 1: Heart 
http://www.pacemakerproject.net/assets/img/heart_anatomy.jpg 
2.1.1 Myocardial Infarction 
 Myocardial infarction, or a heart attack, generally occurs due to the interruption of blood 
supply to part of the heart. Damage occurs if blood flow is not restored to the organ within 20 to 40 
minutes of the blockage (Zafari & Afonso, 2010). The result of blood interruption causes 
irreversible death of the heart muscle. A heart attack is usually due to the narrowing or blockage of a 
coronary artery. These blockages usually arise from a buildup of plaque or a rupture in the wall of 
the artery. Approximately one million Americans suffer a heart attack each year, and four hundred 
thousand of them die as a result of their heart attack (Kulick & Lee, 2010). Most heart attacks are 
minor and people ignore them because they confuse the chest pains with other problems. 
Death is more likely to take place when symptoms are ignored or a more fatal attack occurs. 
When it comes to medical treatment, the aim is to unblock the affected artery and restore blood 
flow to the area of the heart in danger as soon as possible. Today there are many medicines that are 
used to reduce the chance of heart attack. Anti-platelet medicines, for example, are used to prevent 
the tendency of platelets to clot and cause blockages (Agnihotri, Madsen, & Daggett Jr., 2003). In 
severe cases defibrillators are used and open heart surgery is common. Transplants can be used if the 
heart is beyond saving, but there is a limited supply of donors. This is why there is so much funding 
going into research for new methods to treat heart failure (Kulick & Lee, 2010). 
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2.2 Tissue Engineering 
WPI’s microthreads are currently pending a US patent. They are created from collagen and 
fibrin using a thread model of in-vitro ACL scaffold regeneration. They are created to have similar 
mechanical and structural properties as collagen threads; they are made up of a structural protein 
that is found in the provisional matrix during wound healing. The focus of microthreads is to 
incorporate them into the process of complex ligament tissue engineering. 
Tissue engineering is a field of biomedical engineering which focuses on biomaterials and 
cells; also is known as regenerative medicine. Most tissue engineering involves biological functions, 
liquids and materials.  Some specific tissue engineering categories are bone, cartilage, and blood 
vessels. When focusing on one aspect scientists must look at the structural and mechanical 
properties that coincide with the specific aspect. When looking into each aspect one must research 
the tissue’s properties and work on improving their functions and growth. Using the properties 
researched and realizing the need for this specific field, much advancement has been made 
(Borenstein, 2008).  
 
2.2.1 Bone Tissue Engineering 
One category of tissue engineering is called bone tissue engineering and works with the 
structure of the bone and properties it holds. Examining these properties they are then used to 
create bone supplements/substitutions. Many of the key factors that go along with bone tissue 
engineering are harvested cells, recombinant signaling molecules and 3D matrices. Using a scaffold 
to attach the harvested cells and improving the growth of the bone, one must make sure the cells 
will multiply and transform to where they contain bone-like properties. Since bone tissue 
engineering technologies have been emerging; more and more techniques have been discovered to 
work and not work. Some current methods of bone replacement are autografts, allografts, and 
metallic replacements. Within those replacements there have been some arising challenges, such as 
the amount of time it takes the cells to transform and survive on scaffold, design systems, complex 
scaffolds, and new biomaterials (Hutmacher, 2000). 
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2.3.2 Cartilage Tissue Engineering 
Another category for tissue engineering focuses on the cartilage engineering. Cartilage is a 
tissue that can sometimes degenerate by causes of trauma and disease. However since this is a new 
focus for tissue engineering the current repair/treatment methods haven’t been perfected yet, but 
does hold a great promise in the future. The basic procedure that has come from cartilage 
engineering is the use of a biocompatible scaffold that holds the bioactive cells needed to 
differentiate the other cells. The best approach of cartilage engineering is using scaffolds that are 
created by natural and synthetic biomaterials. Over the past few years numerous advances have 
come out that pertain to cartilage tissue engineering. Such are cell–scaffold composites which are to 
help with the lack of cell retention rate. In addition the scaffold being used should almost be 
identical to what the repaired tissue is in order to be successful. A second advancement is the use of 
mesenchymal progenitor or stem cells for cartilage engineering. Using these cells provide less of a 
concern when looking at the donor site, lifespan and cell dedifferentiation. With these advancements 
already scientists are looking to overcome more challenges such as if the tissue has a hostile 
environment or if this can be combined with gene therapy (Cancedda, Dozin, Giannoni, & Quarto, 
2003).  
 
2.3.3 Blood Vessel Tissue Engineering 
Blood vessel tissue engineering is becoming more and more important in the tissue 
engineering field. The approach to blood vessel engineering is re-cellularization, which occurs when 
one strips the living cells from the donor leaving the extra matrix as a scaffold. Once the scaffold is 
formed it is seeded with the new cells which are able to form back into the original tissue because of 
how the scaffold is structured. Re-cellularization is becoming more and more frequent in 
laboratories, and even in bone tissue engineering. One advancement scientist had discovered is using 
adult stem cells to created functional blood vessels that can later replace synthetic grafts which are 
usually require in vascular bypass surgeries. They had determined that one can build the blood vessel 
using the donor’s tissue and an animal’s adult stem cells, using these blood vessel the complications 
of the surgery would be reduced. Blood vessels have also been created another way which is to 
harvest skin cells and remove them leaving just the scaffold and used endothelial cells of the patients 
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because they had discovered that the fibroblasts can clog the blood vessel. These endothelial cells 
are able to hold a smooth blood flow in the interior of the vessel created. Today blood vessel 
engineering is proven to be used in kidney dialysis and to have been effective and successful (Rhima 
& Niklason, 2006).  
 
2.3.4 Tissue Engineering in the Future 
Tissue engineering has clearly become an advancing study in the biomedical field. A great 
contribution to the reason it has been advancing so rapidly, is the need to transplant organs, and 
tissue growth/replacement. This specific type of engineering incorporates biologists, chemical 
engineers, material scientists, surgeons, and other clinical researchers, which is important because 
each role plays a key part in coming up with different tissue engineering procedures. The greatest 
advancement is the focus of skin tissue and the ability of skin grafts and using the patient’s own skin 
cells to repair the skin of patients with skin disorders or burn victims. However over the next few 
years there will be many obstacles that scientists must overcome such as the lifespan of the cells, 
how long it takes the tissue re-growth to become effective, how many times one must go through 
surgery, and if there is an immunity rejection when using a donor’s cells into a patient’s body (Ringe, 
Haupl, & Sittinger, 2007). 
 
2.3 Mesenchymal Stem Cells 
Stem cells are very unique cells that can undergo differentiation into a variety of specialized 
cell types.  They also maintain the ability to proliferate while maintaining an undifferentiated state.  
The discovery of human mesenchymal stem cells (hMSCs) has been a suggested pathway to bypass 
ethical hardships confronted by embryonic stem (ES) cell research (Odorico, 2001). Furthermore, 
while ES cells can theoretically differentiate into all of the cells in the body, HMSCs with their multi-
potent characteristics can be isolated from adult bone marrow and induced in vitro and in vivo to 
differentiate into an array of cells that constitute bone, cartilage, fat, muscle, and other kinds of 
connective tissue such as tendon (Liechty, 2000). Bone marrow is considered the top candidate for 
isolation of mesenchymal stem cells because they exhibit a high congregation of MSCs while still 
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remaining fairly accessible.  HMSCs can be obtained in large quantities, cultured, and frozen for 
preservation without losing their capacity to form a variety of cell types, including cardiomyocytes. 
Due to these versatile qualities, HMSCs are the best candidate for cell delivery for cardiac tissue 
among numerous adult stem cells (Toma, 2002). 
 
2.3.1 Implantation and Experimentation with Mesenchymal Stem Cells 
The goal in the implantation and experimentation of hMSCs is to manipulate them in such a 
way that they can express cardiogenic markers.  However, the techniques used to stimulate myogenic 
differentiation in hMSCs vary.  Experimental data produced by Strauer and colleagues in their study 
titled, Repair of Infarcted Myocardium by Autologous Intracoronary Mononuclear Bone Marrow Cell 
Transplantation in Humans, suggest that bone marrow-derived cells may contribute to the healing of 
myocardial infarction (MI) (Rangappa, 2003). The method used in their study was to treat 10 
patients by intracoronary transplantation of autologous, mononuclear bone marrow cells (BMCs) via 
balloon catheter in addition to standard therapy in another 10 patients after MI.  In the following 3 
months, the infarct region had decreased significantly within the cell therapy group and was also 
significantly smaller compared with the standard therapy group.  While infarction wall movement 
velocity increased significantly only in the cell therapy group, further cardiac examinations that were 
performed for the cell therapy group showed significant improvement in stroke volume index, left 
ventricular end-systolic volume and contractility, and myocardial perfusion of the infarct region.  
These results suggest that selective intracoronary transplantation of autologous, mononuclear BMCs 
is safe and seems to be effective under clinical conditions (Strauer, 2002). 
 
In a similar study titled, autologous bone-marrow stem-cell transplantation for myocardial regeneration, 
tests were concluded using the direct injection technique in six human patients. All of the patients 
had experienced MI and undergone coronary artery bypass grafting (CABG).  Surgeons injected up 
to 1.5×106 autologous AC133+ bone-marrow cells into the infarct border zone in each patient. In 
the following 3-9 months after the surgery, the global left-ventricular function had improved in four 
of the patients, and infarct tissue perfusion had significantly improved in five of the patients. These 
results suggest implantation of AC133+ stem cells to the heart is safe and might induce 
angiogenesis, therefore improving perfusion of the infarcted myocardium (Stamm, 2003). 
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2.3.1 Culturing hMSCs 
The hMSCs are first isolated using a healthy donor.  The MSCs from the marrow sample can 
then be cultured and grown in a petri dish containing human mesenchymal stem cell media with 
basil media and fetal bovine serum in order to acquire the cells needed for co-culturing with human 
cardiomyocytes. Under culture conditions, when there is direct contact of cardiomyocytes and 
hMSCs, the hMSCs begin to express the cardiac specific proteins myosin heavy chain, β-actin, and 
Troponin-T.  During co-culturing human cardiomyocytes can be labeled with a fluorescent indicator 
cell sorting and then mixed with the hMSCs in a smooth muscle medium and seeded at the desired 
cell density.  Cells should be cultured in an incubator at 37°C for duration of 48 hours.  Once 48 
hours has passed the cells can washed with buffered saline solution to remove excess fluorescent 
label.  Trypsin can be added to detach the cells from the surface of the Petri dish (Zafari & Afonso, 
2010) 
 
2.4 Microthread Seeding Procedure 
The microthreads that are inserted into the heart must have a certain number of cells 
attached in order for them to be effective. There are many things that the cells will need in order to 
survive and adhere to the microthreads including, temperature, fresh media and a strong ECM 
(extracellular matrix). HMSCs are placed in to the bioreactor with the purpose to act as a stable 
environment for the cells to live and naturally adhere to the microthread rather than the surrounding 
walls.  
The exact procedure of the seeding the microthreads involves many steps and different 
chemicals to feed cells, and hydrate the threads. The first step in the process is the removal of cells 
from a flask through the use of Trypsin. HMSCs are anchorage dependent and the Trypsin is an 
enzyme that will release the cells from the flask. Once returned to a stable environment the hMSCs 
will re-anchor. Next the cells are spun in a centrifuge and the excess Trypsin is removed. The cells 
are then placed into a media that contains a serum containing proteins that will stop the actions of 
the Trypsin. Before the cells are placed in the bioreactor with the threads, the threads are then 
hydrated in order to increase cell adhesion. Since the cells are super concentrated they require a large 
volume of media in the bioreactor in order to survive. Inefficient levels of media in the bioreactor 
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can lead to high levels of waste which could be harmful to the cells and result in dead cells remaining 
adhered to the threads. The bioreactors are placed into a plastic vial which attaches to a rotator and 
the entire assembly is placed in an incubator. Currently the cells are incubated for approximately 24 
hours before they are ready to be used for implementation. For a complete and step by step 
procedure refer to Appendix A: Microthread Seeding Procedure. 
Different approaches to this process could be taken to perfect the cell seeding system. 
Larger volumes of media could be used while maintaining the same percentage of cells to possible 
yield a higher adhesion amount. There is also the possibility of having communal bioreactors in 
which multiple threads are seeded at once. Also the amount of time that the time they are incubated 
for has yet to be thoroughly researched.     
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3.0 Project Strategy 
This project was completed in two stages, one being completed in December 2010 and the 
second in May 2011. The two stages were necessary because Ben Parkhurst would be graduating in 
December 2010 and the three other group members would complete and carry out the remainder of 
the project. Ben focused on improving the current design of the bioreactor, which had many issues. 
The rest of the team continued on with research and examined transportation methods, storage on 
site, preparation prior to delivery, and shelf life. Dr. Gaudette was an asset throughout the entire 
project where he played the roles of both client and advisor. 
3.1 Project Hypothesis 
The current method used for preparing cell seeded microthreads is time consuming 
procedure. For one this needs to be changed due to time constraints and safety. We aim to design a 
device that will satisfy all of the objectives and functions that the previous/current device hadn’t 
satisfied. 
3.2 Project Assumptions 
We assume that this device should be able to hold eight microthreads, eight being the ideal 
number because the current device holds one and the there is an average need of four to six 
microthreads per a surgery so the extra two can allow for backup. From research it shows that the 
device should have a shelf life of one week and that it should be accessible for both the lab 
technician and the doctor. 
3.3 Project Goals 
The goal of the project is to create a device that will minimize preparation time and 
maximize shelf life while keeping the device safe and sterile. When incorporating these goals this 
device must go through various testing to make sure the microthreads produce viable cells. This 
device would be created in two parts, one finishing up the general prototype by December of 2010 
and then further modified and tested the remainder of the year and to be finished by April of 2011. 
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4.0 Alternative Designs 
This chapter discusses the primary attributes that must be met in order for the device to be 
considered successful. The objectives, functions, constraints, and specifications helped create a more 
detailed and thorough client statement. Once the client statement was extensively revised, design 
alternatives were then generated and explored. 
4.1 Initial Client Statement 
The initial client statement was a vague description of the problem that needed to be solved 
and it needed both clarification and specification. Extensive background research on relative topics, 
such as, stem cell research, cell culture and storage, cryopreservation, and standard operating 
procedures was done in order to gain a better understanding of the factors involved. Informal 
interviews were done with Dr. Gaudette as well as students who had been working directly with the 
original bioreactor were held to find limitations and dislikes. Some of the major concerns with this 
design involved an exposed needle that presented safety issues, as well as the two plastic clamps 
which made the device awkward to work with (shown in Figure 2: Current Method of Bioreactor). 
 
Figure 2: Current Method of Bioreactor 
Up to this point, no research had looked into the longevity of the cells if kept in this bioreactor. 
After conducting this background research and having a more elaborate understanding of the device, 
we formulated a revised client statement: 
The initial client statement was as follows: 
Design a system to deliver cell seeded microthreads to the clinic.  The system should consider storage on site; preparation 
prior to delivery and shelf life.  
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4.2 Objectives, Functions & Specifications 
When given the initial client statement we then had to analyze it and come up with a list on 
objectives and functions. Once the list of objectives and functions were created we then had to 
come up with a way of ranking them from the most important to the least. In order to rank these we 
used a pairwise comparison chart for both functions and objectives shown in Table 1: Blank 
Objective Pairwise Comparison Chart and Table 2: Blank Function Pairwise Comparison Chart. 
After developing a ranking of the objectives and functions we used the initial client statement and 
further research to develop specifications, and constraints for a new device to deliver cell seeded 
microthreads to the clinic. The system should consider storage on site, preparation prior to delivery 
and shelf life. To see our completed charts for objectives and functions refer to Appendix B: 
Objective Pairwise and Comparison Chart and Appendix C: Functions Pairwise and Comparison 
Chart.. 
Objectives             
To establish the following objectives, the question “What must the device be?” was 
answered. 
Objective # 1: The device must be safe. 
Safety was ranked the most important objective involved in our project because without the 
wellbeing of the user and cells, our device would not be feasible. The original bioreactor 
design contained an exposed needle that created a serious safety concern for any one coming 
in contact with it. There is a lot of handling required with the bioreactor when it is being 
prepared for seeding and prior to surgery when the sutures are removed for implantation. 
The safety of the cells was another important aspect of safety that we worked on. The cells 
would have to have durable packaging, also be kept from being shaken, exposure to extreme 
temperatures, UV protective covering; covering from unwanted biological agents, and time 
out of incubator must be minimized. 
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Objective # 2: The device must maintain sterility. 
To maintain the life of the cells, the device needed to be sterilizable. We considered many 
methods of sterilization such as using an autoclave, ethylene oxide and cold sterilization.  If 
the device could not be sterilized, it would not be accepted under the guidelines of the FDA 
for a medical device. The sterilization is also necessary to stop and prevent airborne 
pathogens or dirt that could hinder the cells. 
Objective # 3: The cells in the device must be kept viable. 
In order to maintain efficacy of the procedure, the cell viability would also have to be 
accounted for. The hMSCs need to be stored in a container that offered them protection 
from contamination from the environment.  The cells would have adhere to the microthread 
in the device or remain alive otherwise the device would be considered a failure. 
Objective # 4: The device must be small. 
For storage and ease of transportation purposes the device must be small and compact and 
fit into the incubator used for the microthreads. 
Objective # 5: The device must be environmentally friendly. 
The device should be for a one time use only, therefore it must be disposable and avoid 
being hazardous to the environment. 
Objective # 6: The device must be user friendly. 
Due to the nature of its use, the device must be deliverable to the heart in a time efficient 
manner 
Functions            
To establish the following functions, the question “What must the device do?” was answered. 
Function # 1: The device must maintain sterility. 
Function # 2: Extended shelf life 
Function # 3: The device must hold multiple threads in device. 
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Function # 4: The device must minimize shelf and storage space. 
Function # 5: The device must minimize preparation time for threads 
Function # 6: The device must be safe 
Constraints             
Although we were presented with minimal constraints, they were all vital for successfully 
completing this project.  The constraints were as follows: 
- Size – Our device would need to be big enough to contain the microthreads and small enough 
to fit in a standard incubator. A small device size was also important to minimize the overall cost 
involved. 
- Time – The device must be completed by April 21, 2011 
- Budget – We were given monetary assistance of $156 per group member 
Specifications            
The following design specifications were developed in order to make this device function. 
- No contamination after 1 week of culturing 
- Maintain a minimum shelf life of 1 week 
- Hold up to 8 microthreads 
- Prototype must fit shape constraints 
- Preparation time in less than 45 minutes 
- No needles exposed 
When developing both the constraints and specifications we used a functions means tree shown in 
Appendix D: Functions and Means Tree. 
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Table 1: Blank Objective Pairwise Comparison Chart 
Pairwise Comparison Chart for Main Objectives 
 
 Envirn. 
Friendly 
Cost 
Efficent 
Durable 
Device 
Sterilizable User 
Friendly 
1 Week 
Shelf-
life 
4 Hr. 
Prep. 
Time 
5 Min. 
Application 
TOTAL 
Enviornmentally 
Friendly 
X         
Cost Efficent  X        
Durable Device   X       
Sterilizable    X      
User Friendly     X     
1 Week Shelf-life      X    
4 Hr. Prep. 
Time 
      X   
5 Min. 
Application 
       X  
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Table 2: Blank Function Pairwise Comparison Chart 
Pairwise Comparison Chart for Main Objectives 
 
 Hold 8 
microthreads 
Cell 
Viability 
Sterility Fast 
delivery 
Device 
Size 
1 
Week 
Shelf-
life 
4 Hr. 
Prep. 
Time 
User 
Safety 
Cell 
Safety 
TOTAL 
Holds 8 
Microthreads 
X          
Cell Viability  X         
Sterility   X        
Fast Delivery    X       
Device Size     X      
1 Week Shelf-
life 
     X     
4 Hr. Prep. 
Time 
      X    
User Safety        X   
Cell Safety         X  
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A series of designs were considered including both communal and individual bioreactors.  
After evaluating our conceptual designs it was decided that the final design would multiple tubes to 
contain a total of 8 microthreads. To achieve our size constraint, a cylindrical design would be 
utilized. A tapered end would be applied to the cylinder allowing it to be inserted into a standard 
rotisserie. The rotisserie machine is a piece of equipment that it used to aid in the process of seeding 
the cells the microthreads. The spinning of this device allows for constant movement of the cells 
and media inside the bioreactor, not allowing it to settle. This cylindrical design resembled the same 
shape as the previous bioreactor that was being used. Finally this design was chosen in order to 
maximize the ease of use for both the lab technicians and the surgeons. 
4.3 Revised Client Statement 
Once the initial client statement was review and objectives, functions, and specifications were 
created (as shown in the next section), a revised client statement was  
The revised cient statement is as follows: 
Design a system of delivering cell seeded microthreads from the laboratory to the operating room of a clinic. This system 
should focus specifically on the time between arrival at the clinic and the time of insertion of cells into patient. This 
design must consider preparation prior to delivery to the patient and also provide a minimum shelf life of one week and 
storage on site. The final design must maximize cell viability while still guaranteeing safety to all the users involved. 
 
4.4 Conceptual Designs 
After compiling a detailed list of objectives, functions, specifications and constraints our 
team began to create basic designs. Brainstorming sessions were held to develop possible designs for 
our device. For each specification we had we created a design that would facilitate it. Here are some 
of the conceptual designs that we created: 
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Figure 3: Conceptual Design 
A circular eight well bioreactor with cap 
 
 
Figure 4: Conceptual Design 
A rectangular eight well bioreactor 
 
 
Figure 5: Conceptual Design 
A square single thread bioreactor 
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Figure 6: Conceptual Design 
A square multiple thread bioreactor 
 
 
Figure 7: Conceptual Design 
Disposable, individually packaged microthread, could use as many desired at once 
 
 
Figure 8: Conceptual Design 
Reusable, individually packaged microthread 
 
 
Figure 9: Conceptual Design 
Petri dish style, eight microthreads with a communal bioreactor 
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4.5 Prototypes 
After choosing the different aspects from many conceptual designs, we formulated a 
preliminary design that would achieve the maximum number of functions. In order to create a 
prototype of this preliminary design, it needed to be drawn in using CAD software. Using 
Solidworks, the design of the prototype was created so that it could be processed by the Rapid 
Prototyping machine. The Rapid Prototyping machine has the ability to print 3D objects, layer by 
layer, out of plastic. A prototype would enable the team to examine the compatibility of the device 
with the microthreads and necessary equipment.  
 
The team developed 3 designs that encompassed the most favorable features of the 
conceptual designs.  With each design we progressively achieved full functionality of our device by 
applying specifications to meet each function. 
4.5.1 Prototype 1 
The first design shown below in Figure 10: Prototype 1 consisted of 8 outer wells with 
grooves connecting to a center holster for the needles. In this design we were able to have prototype 
device hold 8 microthreads while extending shelf life through the convenience of being able to 
change the media in the device. This device is also small enough to fit on the rotator and into the 
incubator which satisfies the function of minimizing shelf and storage space. This device was able to 
be autoclaved and so therefor satisfies the function of sterility and keeping the cells safe. 
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Figure 10: Prototype 1 
 
4.5.2 Protoype 2 
The device was then reworked to achieve more of our desired functions and was successful 
in still meeting the already achieved functions of the device. Although the device continued having 
major success, the design was slightly detrimental to the user because of the needles’ communal 
holster. Having all the needles sharing the same resting spot caused a safety issue as it also made it 
difficult to grab one single needle at a time. So the second design shown below in Figure 11: 
Prototype 2 consisted of 8 wells and the needles would now rest within the grooves extruding 
downwards into the device and pointing outwards away from the center of the device. 
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Figure 11: Prototype 2 
 
4.5.3 Prototype 3 
The device was then reworked one last final time to achieve all of its desired functions and 
was successful in still meeting the already achieved functions of the device. The third and final 
device shown in Figure 12: Prototype 3 also consisted of 8 wells with grooves extruding downwards 
into the device and pointing outwards away from the center of the device. However, the design still 
needed to account for proper media, nutrients, and gas exchange. Therefore each well was 
connected to one of its neighboring wells.  Moreover every cut and extrude made to the device 
would now be connected to every other cut and extrude on the device for improved air flow. 
30 
 
 
Figure 12: Prototype 3 
The full device is shown in Appendix E: Device Components in Complete Arrangement. 
The idea of 2 washer pieces shown below in Figure 13: Washer was created to substitute for the 
current method using plastic clamps to contain the media, cells, and microthread within the 
bioreactor.  The washers go on the top and bottom of the device and are sealed in by two detachable 
caps (shown below in Figure 14: Caps for Final Design) that are tailored to fit the dimensions of a 
standard rotator device.  
 
 
               Figure 13: Washer 
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Figure 14: Caps for Final Design 
The bottom cap for the device shown on the right side, and the top cap for the device is shown on the left side. 
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5.0 Methodology 
This chapter encompasses the methods for producing hMSCs and fibrin microthreads as well as 
testing the selected materials and methods in maintain cell viability while inside the device.  The 
production of microthreads, methods for seeding, and qualitative methods to confirm attachment of 
hMSCs to fibrin microthreads are discussed. 
5.1.1 Cell Culture 
A majority of the experiments that were administered during the course of this project 
required the use of cultured stem cells.  Experiments were performed using P6 cells cultured in 
Dulbeccos Modified Eagle’s Medium (DMEM) with 10% Fetal Bovine Serum (FBS) and 1% 
Penicillin/Streptomycin (P/S).  In order to maintain sterility, all cell culture experiments were 
completed aseptically in a biological safety hood.  An exact cell culture protocol can be viewed in 
Appendix F: Cell Culture Protocol (Fakharzadeh, 2009). Cells used in each experiment were 
incubated at 5% CO2 and 37°C in tissue culture treated flasks. 
5.1.2 Fibrin Mircothread Production 
Fibrin microthreads were self-assembled from solutions of fibrinogen and thrombin.  The 
two solutions were extruded through polyethylene tubing at a pump speed of .032 mL/min into a 
bath of 10 mM HEPES, pH 7.4 maintained at room temperature.  Individual threads of less than 
100 µm diameter each were produced and bundled into groups of eight with 0.6-0.8 mm thickness 
by twisting the microthreads together, dousing them in DI H2O, and allowing them to dry.  The 
exact microthread bundling protocol can be viewed in Appendix G: Microthread Bundling Protocol 
(Fakharzadeh, 2009) 
5.1.3 Dynamic Seeding: Rotational Method 
Following sterilization, with the microthreads already inside of the device each bioreactor 
was injected with 300 µL of cell suspension at a concentration of 75,000 cells /100µL using a 1cc 
syringe and a 27 gauge needle.  The device was then placed onto the rotator at 4 RPM and then 
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finally placed into the incubator at 5% CO2 and 37% and rotated for 24 hours.  An exact seeding 
protocol can be seen in Appendix A: Microthread Seeding Procedure. 
5.2 Cell Quantitative/QualitativeMethods 
To test cell quantity and quality, the use of a fluorescent dye such as Hoechst nuclear stain 
and Phallodincan be used. By staining the microthreads with the Hoechst dye, the seeded cells can 
be quantified and qualified under an optical microscope. The Hoechst dye binds to the nucleus 
within the cells and stains green, which when excited at 390nm, will emit a blue light at 
approximately 490nm.   The Phallodin dye binds to the filamentous actin (f-actin) and stains green, 
shown in the  Figure 15: F-Actin. 
 
            Figure 15: F-Actin 
          Here the F-Actin is shown through the staining process 
5.2.1 Hoechst Nuclear Stain & Phallodin F-actin Stain 
To conduct a Hoechst nuclear stain, after seeding the microthreads, they are washed in 
DPBS for 15 minutes. The threads are then fixed using 4% paraformaldehydefor 15 minutes. A 
dilution of 1:6000 Hoechst and DPBS is added, and the solution is let to sit for another 15 minutes. 
Finally the threads are washed in DPBS for 15 minutes. The threads are then mounted on glass 
slides in order to view them under the optical microscope. 
5.2.2 Hemocytometer (Fakharzadeh, 2009) 
The last method of cell quantification is the use of a hemocytometer. The media is removed 
from the flask, then 5mL of DPBS is added and the flask is incubated for 5 minutes. After the 5 
minutes, the DPBS is removed and another 5mL of trypsin is added to the flask of cells and left to 
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incubate for 5 minutes. After incubation, cell detachment is ensured through the use of a 
microscope. Five mL of media is added, and the mixture is transferred to a 15mL conical tube. This 
tube is centrifuged for 5 minutes at 1,000rpm. The media is then aspirated and 0.5mL of media is 
added. Ten 10μL of the cell mix is mixed with 10μL of trypan blue dye in a micro-centrifuge tube. A 
coverslip is placed on the hemocytometer and 10μL of the cell/trypan blue solution is added to one 
square of the hemocytometer. This is placed under microscope and the cells are counted in the 
middle square. If 100 cells are observed before counting all five squares, counting may cease. 
However, if less than 100 cells are observed in that first square, counting is continued into the other 
squares. In order to determine the number of cells in the flask Equation 1 and Equation 2 were 
used. 
Equation 1: Determining Number of Cells in Flask 1 
 
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑐𝑜𝑢𝑛𝑡𝑒𝑑
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑠𝑞𝑢𝑎𝑟𝑒𝑠 𝑐𝑜𝑢𝑛𝑡𝑒𝑑 ∗ 104 ∗ 2 = 𝐶𝑒𝑙𝑙𝑠1 𝑚𝐿 𝑜𝑓 𝑚𝑒𝑑𝑖𝑎 
 
Equation 2: Determining Number of Cells in Flask 2 
 
𝑇𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 = 𝐶𝑒𝑙𝑙𝑠1 𝑚𝐿 𝑜𝑓 𝑚𝑒𝑑𝑖𝑎 ∗ 𝐶𝑒𝑙𝑙𝑠 𝑠𝑢𝑠𝑝𝑒𝑛𝑠𝑖𝑜𝑛 𝑣𝑜𝑙𝑢𝑚𝑒 (0.5 𝑚𝐿) 
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6.0 Analysis and Discussion 
Previously the device being used as a bioreactor was complicated and needed a lot of 
developments. Our group met the objectives of designing a system for expediting and improving the 
process of preparing cell seeded microthreads for the clinic. We made significant improvements to 
this medical procedure by meeting every single one of our functions and specifications. To satisfy all 
the functions the device needed to be sterilizable, extend shelf life, hold multiple threads, minimize 
shelf and storage space, minimize preparation time for the threads, and be safe. 
 To solve the sterility problem the new bioreactor was made out of a strong plastic that can be 
easily sterilized. Any autoclave or gas sterilizer has the ability to sterilize the material that was chosen 
for the prototypes. This hard plastic not only allows for the device to be constantly handled without 
damaging the cells or threads, but it can also be sterilized and reused again after medical procedures. 
This is an excellent plus because the previous design could only be used once before being thrown 
out. Additionally this allows for companies to save money since they do not have to constantly buy 
new storage devices for the microthreads. 
 To extend shelf life the entire model was designed to be easy to handle and ship, but still 
protect the cells, the media, and the microthreads inside the device. In addition to the durable plastic 
material helping to the extend shelf life, the design of the model was developed to act as a protective 
shell as well. Testing proved that the design did provide protection for all the contents in the device. 
The washers and caps also ensure that everything stays secure during any type of shipping that could 
occur. As long as the cell seeded microthreads are constantly fed with media and proper storage of 
the model is ensured, the shelf life of the device can be extended to the desired time period. 
 When it came to satisfying the multiple thread specification, we decided that the device should 
hold eight microthreads. We were able to come to this conclusion because during current medical 
procedures a surgeon would use six microthreads on average. With our model, eight microthreads 
allows for two extra microthreads to be available in case anything goes wrong with the other threads 
during surgery. Compared to the current method, which only holds a single microthread, this new 
design that holds eight at one time reduces the amount of time needed for seeding and application. 
Since multiple sutures are needed for a single surgery this also reduces the number of materials 
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involved in the process. In the end, this design requirement allows for an easier and more efficient 
system of preparing cell-seeded microthreads for the clinic. 
Minimization of shelf and storage space was not a problem for even our original prototype. 
During the design process we made sure that the device was going to be compact, portable, and still 
fit properly into the rotator and incubator. We modeled our design to mimic the tubes that are 
currently used in the rotator for different applications. The difference between our model and 
current tubes is that ours can stand up on its own. There is no need for any other storage apparatus 
to hold the device. This cylindrical based design is very small in size and does indeed minimize shelf 
and storage space. 
 Preparation time for the threads was minimized by the individual wells created for the each of 
the eight microthreads. The diameter of each of the wells was set to the perfect size so the tubes can 
easily pass in and out of the device. During an operation the surgeon can use the needle drivers to 
grab a thread without confusion. The device is made so there is no resistance when a microthread 
needs to be removed from a well. Since there will be no fumbling with the threads, there is 
essentially no preparation time needed to prepare a microthread. This is substantially better than the 
current design method because no clips need to be removed from the individual threads in order to 
use them in surgery.  
 User safety was improved by creating an area that will contain the needle and protect the 
users. With the needle safety placed into the groove that was created, it is difficult for an accidental 
puncture to occur when handled properly. The grooves also allow the needles to be hidden inside 
the device rather than sticking out of the top and crisscrossing. The previous design used a flexible 
piece of plastic tubing that could damage the cells on the microthread if squeezed unintentionally. 
With constant testing, our final device that we developed did satisfy all our functions and 
specifications. All in all, the objectives of this project were completed on time and done within the 
stated budget. 
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7.0 Manufacturing, Ethics and Influences 
The price of the prototype that we had made was very inexpensive costing only about 
$15.00. This device was not only cheap but easy to manufacture because it can be created within 12 
hours. This bioreactor device design could be machined out of any material. All of the holes and 
physical aspects of the device can be machined using only a small number of machines including a 
drill and a reciprocating saw. A cheap and easy to produce device would create a low cost for not 
only laboratories but also for the patients receiving treatment. This device could be made out of any 
number of materials and does not require any hazardous or scarce materials.  
 
This device combined with microthreads inside it will offer a beneficial treatment for 
patients who have suffered a heart attack. This device will have a very positive societal impact 
because it will make the lives of all the users significantly easier. The simplicity of this device allows 
for a decreased preparation time by lowering the number of required materials (See Appendix H: 
Putting the Device Together). The communal design of this bioreactor, among other factors, will 
lower the application time which means a decrease in medical bills as well as a shorter recovery time.  
 
This product doesn’t pose any political concerns because it will help people live better lives. In 
terms of ethics, this medical device only presents effects as it will be in the technicians, doctors and 
patients best interest to use it. The device itself can only help people and will assist in creating a 
good and satisfying life. The communal bioreactor created for this project will house 8 microthreads 
that will be designed to regenerate dead tissue which lead to an increase in personal heath for many 
people.  
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8.0 Conclusion 
After all of the testing and analysis was completed (as outlined in the previous chapters), the 
final design that was created successfully met all of the specifications, objectives, functions, and 
found a solution to limitations on previous methods. The team decided that this design was the best 
way to satisfy all of the functions and objects. The testing results showed that the needles 
successfully were all able to be placed inside the device without crossing and that the device was able 
to fit comfortably in the rotator device.  It was made sure that the device was able to be sterilized 
without being damaged or changed. The device also allowed for gas exchange which was one of the 
main reasons we looked to improve the previous design. As seen below in Figure 16: Final 
Prototype the new device is noticeable different in shape and size. Unlike the current method the 
new method is a lot more compact and efficient.  
 
Figure 16: Final Prototype 
Overall, after reviewing all of the analyses it was proven that we developed a suitable device 
to contain microthreads according to the objectives and functions we set for the device at the 
beginning. When reviewing the initial client statement the device was able to meet the goal of the 
initial client statement as well as the revised client statement. The device that was created can be 
easily manufactured and is very user friendly to both the lab technician and doctor. This device 
enhances cell viability and shortens preparation time.  Theoretically the device would be enclosed in 
a sterilized bag ready for use right off the shelves. After confirming all of the goals were successfully 
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completed it was determined that this device created an improved way to prepare fibrin 
microthreads for the clinic (See Appendix H: Putting the Device Together). 
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9.0 Recommendations 
Even though the final design surpassed all of the functions and objectives there still is more 
information that needs to be looked into. There needs to be additional testing to look over what 
type of material would be the best to build this device out of. The device that is created right now is 
a rapid model prototype and even though it works we would like to explore different materials to get 
the best possible results of cell viability and shelf life, when producing and manufacturing this 
device. 
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Appendix A: Microthread Seeding Procedure 
MATERIALS 
 
- 1.98 mm I.D. Silastic tubing 
- (2) Side clamps 
- Size 18 half circle tapered suture needle 
- Biological microthread bundle (collagen/biodegradable microthreads) 
- PBS 
- Sterile PBS 
- 70% Ethanol 
- (6) Sterile syringes 
- 27G needle (without sharp tip) 
- Sterile 1 cc syringe 
- Cell suspension (100,000 cells/100 μL) 
- 50 mL conical tube 
 
 
Procedure 
 
1.   Use a new syringe to expel all sterile PBS from the bioreactor immediately before seeding 
 
2.   Use a new syringe (1 cc maximum) to inject 100 μL of cell suspension (my cell 
concentration is 100,000 cells/100 μL) into the bioreactor 
 
3.   After seeding, remove 27G needle from bioreactor 
 
4.   Place bioreactor in 50 mL conical tube 
 
5.   Place bioreactor in MACSmix tube rotator and rotate at 4 RPM (lowest setting) for 24 
hours 
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Appendix B: Objective Pairwise and Comparison Chart  
 Envirn. 
Friendly 
Cost 
Efficent 
Durable 
Device 
Sterilizable User 
Friendly 
1 Week 
Shelf-
life 
4 Hr. 
Prep. 
Time 
5 Min. 
Application 
TOTAL 
Enviornmentally 
Friendly 
X -0.5 -0.5 -0.5 -0.5 -0.5 -0.5 -0.5 -3.5 
Cost Efficent 0.5 X -0.5 -0.5 0 -0.5 -0.5 -0.5 -2.0 
Durable Device 0.5 0.5 X -0.5 0 -0.5 0 0 0 
Sterilizable 0.5 0.5 0.5 X 0.5 0 0.5 0.5 3 
User Friendly 0.5 0 -0.5 -0.5 X -0.5 0 -0.5 -1.5 
1 Week Shelf-life 0.5 0.5 0.5 -0.5 0.5 X 0.5 0 2 
4 Hr. Prep. 
Time 
0.5 0.5 -0.5 0.5 0 -0.5 X 0 0.5 
5 Min. 
Application 
0.5 0.5 0 -0.5 0.5 0 0 X 1 
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Appendix C: Functions Pairwise and Comparison Chart 
 Hold 8 
microthreads 
Cell 
Viability 
Sterility Fast 
delivery 
Device 
Size 
1 Week 
Shelf-
life 
4 Hr. 
Prep. 
Time 
User 
Safety 
Cell 
Safety 
TOTAL 
Holds 8 
Microthreads 
X -0.5 -0.5 0.5 -0.5 -0.5 -0.5 -0.5 -0.5 -3 
Cell Viability 0.5 X 0 0.5 0.5 0.5 0.5 0 0 2.5 
Sterility  0.5 0 X 0.5 0.5 0.5 0.5 0 0 2.5 
Fast Delivery -0.5 -0.5 -0.5 X -0.5 0 -0.5 -0.5 -0.5 -3.5 
Device Size 0.5 -0.5 0.5 0.5 X 0.5 0 -0.5 -0.5 0.5 
1 Week Shelf-life 0.5 -0.5 -0.5 0.5 0 X 0.5 -0.5 -0.5 -0.5 
4 Hr. Prep. 
Time 
0.5 -0.5 -0.5 0.5 0 0 X -0.5 -0.5 -1 
User Safety 0.5 0.5 0.5 0.5 0.5 0.5 0.5 X 0 3.5 
Cell Safety 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0 X 3.5 
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Appendix D: Functions and Means Tree 
Prepare Cell seeded 
microthreads for clinic 
Physical 
sterilizable 
autoclavable 
ethylene oxide 
cold sterilization 
hold multiple 
threads 
8 individual 
bioreactors 
one communal 
bioreactor 
Size 
fit in standard cell 
culture incubator 
tightly pack 
bioreactors 
together 
User Friendly 
minimize number 
of parts 
non-bulky design 
Safety 
Cell Safety 
air tight packaging 
durable packaging 
bio-agents 
temperature 
control  
UV protective 
cover 
minimize time out 
of incubator 
o2 and CO2 regulation 
User Safety 
No exposure to 
cells 
No exposed 
needles 
hard 
cap/container 
well or depression 
"cork" 
sleeve (with an 
antiseptic) 
Time 
one week shelf 
life(viability) 
freeze in liquid 
nitrogen 
store in ultra low 
freezer 
store in freezer 
store in fridge 
replace cell media 
one week sterility 
air tight device 
secondary 
packaging 
antiseptics 
<10% change in 
failure load after 
freezing 
freeze cells 
seprately from 
threads 
<5 minute loading 
time 
prepackaging 
rubber stopper in 
device (like syrum 
bottles) 
have cells frozen 
on threads ahead 
of time 
<5 minute 
delivery 
threads easily 
removable from 
container 
minimize 
removal/delivery 
steps 
<4 hr prep time 
prepackaging 
prefrozen cells on 
threads 
threads bundled 
and placed on 
needles 
Budget Environment 
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Appendix E: Device Components in Complete Arrangement 
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Appendix F: Cell Culture Protocol (Fakharzadeh, 2009) 
MATERIALS 
 
- STERILE media: DMEM (Dulbecco’s Modified Eagle’s Medium) with 10% FBS 
Fetal Bovine Serum) and 1% P/S (Penicillin and Streptomycin) 
- STERILE DPBS (Dulbecco’s Phosphate Buffered Saline), 1X 
- Trypsin EDTA, 1X 
- 10 μL, 100 μL, and 1000 μL pipettes 
- Pipette boy 
- STERILE 10 μL, 100 μL, and 1000 μL pipette tips 
- STERILE T75 or T25 cell culture flask 
- STERILE Pasteur pipettes 
- STERILE serological pipettes 
- STERILE 15 mL conical tube 
- Trypan blue solution in PBS (50% trypan blue solution, 50% PBS) 
- 0.7 mL microcentrifuge tube 
- Hemocytometer 
 
Procedure 
 
1.   Look at cells under microscope to ensure at least 80% confluency 
2.   Remove media from flask 
3.   Add 5mL DPBS to flask 
4.   Incubate for 5 minutes in hood 
5.   Remove DPBS from flask 
6.   Add 5mL trypsin to flask 
7.   Incubate for 5 minutes in incubator 
8.   Look at flask under inverted microscope to ensure cell detachment 
9.   Add 5mL media to flask and transfer cell suspension to 15mL conical tube 
10. Centrifuge cell suspension at 1000 RPM for 5 minutes (don’t forget counter weight) 
11. Prepare hemocytometer and allow it to dry 
12. Aspirate supernatant (everything except cell pellet at bottom of conical tube) 
13. Add 0.5mL of media (make sure to mix solution) 
14. Add 10μL of cell suspension to 10μL of trypan blue solution in 0.7mL microcentrifuge tube 
15. Put coverslip on hemocytometer and add 10μL of combined trypan blue solution/cell 
suspension to one square 
16. Count cells with microscope starting on the middle squar e segment. 
17. Count cells in the 5 squares. If you reach 100 cells counted before counting all 5 squares you 
may stop counting. Make sure you count all of the cells in each square you choose to count 
(don’t stop half way!) 
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18. If you do not count 100 cells in the 5 squares you must add the remainder of the trypan blue 
solution/cell suspension to the other square on the hemocytometer 
19. Repeat step 16 if you need to count more squares 
20. Use the following equation to determine the number of cells in your flask: 
 
 
 
 
 
 
21. If seeding is desired, use the following equation to determine the required total volume of cell 
suspension: 
So, for example when I seed my microthreads I need a volume of 100μL per seeding tube and I 
want 100,000 cells in that 100μL of cell suspension. So I would plug the following values into 
this equation, assuming that I have 500,000 cells: 
 
For this example Y would equal 500μL.  Since I already added 500μL to the cells after centrifugation I 
don’t need to add any more media in this case.  So whenever you start with the cell suspension of 
500μL, you need to subtract that from the Y value you solved for (Y – 500). 
22. If only subculture is desired, use the equation above to make a cell concentration of   
 
 
23. After seeding or when subculturing the remaining cell suspension must be transferred into 
either T75 or T25 flasks. 500,000 cells should be put into a T75 flask and 160,000 cells should be 
put into a T25 flask to ensure proper growth 
 
24. After cells suspension has been added to the appropriate size flask(s) calculate the amount of 
media that you must add to create a total volume of 10mL for T75 flasks or 3mL for T25 flasks. 
 
25. Put cells back in incubator and feed them the NEXT DAY 
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Appendix G: Microthread Bundling Protocol (Fakharzadeh, 2009) 
Materials 
- Gloves 
- Overhead projector screen 
- Black mat 
- 2 pairs of forceps 
- 2 pieces of tape 
- DI H20 
- Fibrin threads 
- Needle 
- Scissors 
 
Procedure 
 
1.   Lay 8 fibrin threads of the same length on the overhead projector screen as close as possible 
 
2.   Push the 8 ends as close as possible and tape them down on the overhead projector 
 
3.   Note: we have no need for the collagen threads because we will have the sheath to protect 
them therefore, we don’t need the added stability/strength associated with the collagen threads 
 
4.   With your dominant hand at the tape end and your non-dominant hand holding the threads 
taught, smooth the DI H2O along the threads using a plastic pipette 
 
5.   Place a kimwipe underneath the threads so they don’t stick to the projector screen 
 
6.   Cut the threads at the un-taped end so they are all the same exact length 
 
7.   Let the threads dry 
 
8.   Measure 4cm of the threads starting from the un-taped end and cut the threads 
 
9.   Pass the threads through the needle using the forceps 
 
10. Wrap the two halves of the thread bundle around itself 
 
11. Wet the threads using lots of DI H2O 
 
12. Twist both strands together and rewet 
 
13. Let the bundle dry 
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Appendix H: Putting the Device Together 
In sterile environment Easy to insert media Device fits on rotator 
Rotator fits in 
incubator with device 
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